Ryan Cohlhepp, who serves as President and Chief Operating Officer of Bicara Therapeutics Inc (NASDAQ: BCAX), sold 12,500 shares of the companys common stock on April 15, 2026, according to a filing. The disposals were executed across multiple trades at prices between $22.58 and $23.255, producing proceeds of $287,591 at an average price of $23.0073 per share.
On the same day, Cohlhepp exercised stock options to acquire 8,000 shares of Bicara common stock at an exercise price of $3.7898, for a total cost of $30,318. After these actions, Cohlhepp is recorded as directly holding 196,141 shares of Bicara Therapeutics common stock.
The insider transactions were carried out pursuant to a Rule 10b5-1 trading plan that Cohlhepp adopted on February 12, 2025. The stock was trading near its 52-week high of $24.25 at the time of the sales, following an approximately 97% increase in the past year.
Observers will note the timing against the companies recent operational and clinical developments. In its fourth-quarter 2025 results, Bicara highlighted a strong cash position alongside encouraging clinical data for its lead candidate, ficerafusp alfa. The company also provided updates on ongoing studies of ficerafusp alfa in head and neck squamous cell carcinoma and metastatic colorectal cancer. Management reported increased operating expenses as part of the companys activity in advancing its programs.
Market response to those disclosures has been constructive among some sell-side analysts. Citizens reiterated a Market Outperform rating and set a $31 price target, citing a valuation approach built on discounted earnings-per-share and revenue multiple analysis. Separately, H.C. Wainwright raised its price target to $42 and maintained a Buy rating, identifying a slate of potential 2026 catalysts that includes presentation of long-term follow-up data from a Phase 1b study at ASCO 2026.
In addition to the regulatory-plan detail and the buy-and-sell mechanics, third-party analysis referenced in filings indicates that the stock appears overvalued relative to its Fair Value in an InvestingPro assessment, which also notes 14 additional ProTips for subscribers. That assessment sits alongside the analyst price-target revisions and the companies own disclosure of its cash position and clinical progress.
The combination of insider selling via a pre-established 10b5-1 plan, concurrent option exercises, a near 52-week high share price, and recent analyst attention frames the recent activity in BCAX. The filings do not attribute motives beyond the mechanics of the trading plan or provide further commentary from company officials.